)
Astrana Health (ASTH) investor relations material
Astrana Health Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue reached a record $1,023.6M, up 7% YoY; adjusted EBITDA was a record $77.2M, up 13%, and adjusted diluted EPS was $0.71.
GAAP net income was $20.3M versus $1.1M; net income attributable to the business was $13.0M versus $0.4M.
Managed care covered ~1.5 million patients across 29 IPAs and a network of more than 20,000 contracted physicians at September 30, 2026.
Growth reflected organic Medicare Advantage expansion, members transitioning to full-risk arrangements, and Prospect acquisition contributions to nine-month results.
Financial highlights
Total revenue rose to $1,023.6M from $956.0M; capitation revenue was $936.7M versus $863.4M, with Q3 capitation growth of 8.5%.
Operating income increased to $39.9M from $19.2M; EBITDA was $58.7M versus $35.5M, and adjusted EBITDA margin was 8% versus 7%.
Nine-month revenue increased 33% to $2,961.2M; adjusted EBITDA rose 39% to $212.4M, and adjusted diluted EPS was $2.25 versus $1.66.
Nine-month free cash flow was $105.4M versus $110.4M YoY; operating cash flow was $117.1M.
Q3 included $5M–$10M of Medicare Advantage risk-adjustment sweep revenue and 2026 MSSP shared-savings accruals, not expected to recur in Q4.
Outlook and guidance
FY26 guidance was narrowed while retaining midpoints: revenue $3.9B–$4.0B, adjusted EBITDA $261M–$274M, and free cash flow $107.5M–$130M.
Q4 guidance is revenue $939M–$1,039M and adjusted EBITDA $48.5M–$61.5M; Q4 is expected to be the year's lowest-profitability quarter.
Management expects at least mid-teens annual adjusted EBITDA growth over the medium term, supported by cohort maturation, risk conversions, new MA partnerships, and operating leverage.
FY27 planning assumes 10%–15% Medicaid membership decline; MA margins are expected to remain stable, with formal FY27 guidance expected alongside Q4 results.
- FY 2023 revenue rose 21%; 2024 guidance targets $1.65B–$1.85B.ASTH
Q4 2023 - AI-driven platform and delegated risk model drive growth, efficiency, and improved outcomes.ASTH
Investor presentation - AI-powered platform delivers scalable value-based care, driving growth, efficiency, and better outcomes.ASTH
Investor presentation - Q2 2026 revenue up 49%, net income more than doubled, and guidance was raised.ASTH
Q2 2026 - Rapid growth, tech-driven efficiencies, and resilient margins amid regulatory shifts.ASTH
Bank of America Global Healthcare Conference 2026 - Q3 revenue up 37% to $478.7M; guidance raised after major acquisitions and capitation growth.ASTH
Q3 2024 - $745M deal expands reach to 1.7M members, with $12M in synergies targeted by 2027.ASTH
M&A Announcement - Q1 revenue up 53% to $620.4M, but profitability declined; 2025 outlook remains robust.ASTH
Q1 2025 - 2024 revenue rose 47% to $2.03B, with Adjusted EBITDA up 16% to $170.4M.ASTH
Q4 2024
)
)
)
)
)
)
)
)